Clinical and Experimental Dermatology最新文献_第10页

Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria. 240 名慢性自发性荨麻疹患者的嗜碱性粒细胞激活试验的相关性。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-16 DOI: 10.1093/ced/llae441

David Pesqué, Evelyn Andrades, Paloma Torres-Bosó, Dulce Soto, Ramon Gimeno, Ramon M Pujol, José Yélamos, Ana M Giménez-Arnau

{"title":"Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria.","authors":"David Pesqué, Evelyn Andrades, Paloma Torres-Bosó, Dulce Soto, Ramon Gimeno, Ramon M Pujol, José Yélamos, Ana M Giménez-Arnau","doi":"10.1093/ced/llae441","DOIUrl":"https://doi.org/10.1093/ced/llae441","url":null,"abstract":"Background: Basophil activation test (BAT) is considered to be the best biomarker to predict autoimmune chronic spontaneous urticaria (aiCSU). To date, few studies have investigated the utility of BAT in real-life clinical practice, the role of aiCSU biomarkers in relation to omalizumab therapy and the association between aiCSU tests.Objectives: This study aimed to analyze the clinical and laboratory features of a prospective cohort with CSU according to their BAT status, as well as to study omalizumab efficacy according to aiCSU biomarkers.Methods: A prospective study was conducted from 2010 to 2024 in patients with CSU. BAT alongside other laboratory tests were performed, and clinical and therapeutic features were prospectively collected. Data obtained was compared according to BAT status. Furthermore, omalizumab drug survival was typified according to aiCSU biomarkers.Results: A total of 240 patients were included in the study. BAT positive patients presented more frequently low IgE levels, higher occurrence of IgG anti-thyroid peroxidase (anti-TPO) positivity, autologous serum skin test (ASST) positivity, basopenia, and eosinopenia. The multivariate logistic regression revealed that ASST (OR:7.69, 95%CI: 2.81-21.0) and anti-TPO (OR:2.63, 95%CI: 1.05-6.61) were associated to BAT positivity. All aiCSU biomarkers (BAT, ASST, combined ASST/BAT positivity and low IgE/anti-TPO+) associated significantly shorter omalizumab survival due to failure. In the cohort, both low IgE/anti-TPO+ and ASST were concordant and associated to BAT.Conclusions: The use of BAT in clinical practice delineates a subgroup of patients with specific clinical, laboratory and therapeutic features, including increased omalizumab failure.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Resistant Case of Centro-Facial Erythema. 一例耐药的中面部红斑病例

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-16 DOI: 10.1093/ced/llae440

Alexandra Banner, Richard Dixon, Sarah Woodrow

引用次数: 0

Early poliosis- and vitiligo-like depigmentation as an indicator of treatment response in patients with uveal melanoma under tebentafusp therapy. 早期多形性和白癜风样色素沉着是特本福斯治疗葡萄膜黑色素瘤患者治疗反应的指标。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-15 DOI: 10.1093/ced/llae427

Charlotte Helf, Katharina C Kähler

引用次数: 0

The Diagnostic Complexities of Reactive Angioendotheliomatosis. 反应性血管内皮瘤病诊断的复杂性。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-15 DOI: 10.1093/ced/llae431

Amelia S I Gelson-Thomas, Kalina Bridgewater, Victoria Vilenchik, Beth Wright, Jon Oxley, Florence Garty, Kiran Singh, Sarah Woodrow, Daniel Keith

引用次数: 0

Refractory papulonodular mucinosis successfully treated with tofacitinib. 托法替尼成功治疗难治性乳头状粘液沉着症

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-15 DOI: 10.1093/ced/llae438

Si-Yu Luo, Sheng Fang

引用次数: 0

Tender indurated patches and plaques on lower limbs. 下肢有触痛的硬化斑块和斑块。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-15 DOI: 10.1093/ced/llae435

Ji Fung Yong, Laoise Griffin, Nesa Samuel Karunadhas, Fergus Macsweeney, Liana Victory, Emily Pender, Michael O'Connell

引用次数: 0

The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study. 替雷珠单抗对中重度银屑病患者生活质量的影响：一项为期 36 周的前瞻性、单中心、真实生活观察研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-14 DOI: 10.1093/ced/llae433

Sara Cacciapuoti, Teresa Battista, Luca Potestio, Massimiliano Scalvenzi, Matteo Megna, Angelo Ruggiero

{"title":"The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study.","authors":"Sara Cacciapuoti, Teresa Battista, Luca Potestio, Massimiliano Scalvenzi, Matteo Megna, Angelo Ruggiero","doi":"10.1093/ced/llae433","DOIUrl":"https://doi.org/10.1093/ced/llae433","url":null,"abstract":"Background: Psoriasis may significantly impact on patients' health related quality of life (HRQoL). Clinical assessment has been combined with HRQoL scores to evaluate the ways that cutaneous disease is a burden to patients. Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for the management of moderate-to-severe plaque psoriasis. The aim of our study was to evaluate the impact of tildrakizumab treatment on psychological field in patients affected by moderate-to-severe plaque psoriasis.Methods: a 36-weeks observational study was carried out enrolling psoriasis patients who initiated treatment with tildrakizumab 100 mg. DLQI and Skindex-16 questionnaire were administered at baseline, week 12, week 24 and week 36. PASI, BSA and pruritus (p)-VAS were also assessed at baseline and at each follow-up.Results: A total of 34 patients were enrolled. Baseline PASI and BSA score were 28.4±5.6 and 38.8±21.4, respectively. Similarly, the impact of psoriasis on HRQoL was collected (DLQI: 26.4±3.2, Skindex-16: 68±5.8, p-VAS: 8.2). Clinical improvement was assessed since week 12 (PASI: 12.4±4.2; BSA: 16.5±7.3), continuing to week 24 (PASI: 4.2±2.8; BSA: 6.1±3.1) and 36 (PASI: 3.6±3.2; BSA: 4.2±1.37). Clinical improvement was accompanied by an improvement in quality of life at week 16 (DLQI: 15.5±2.9; Skindex-16: 28.2±4.2; p-VAS: 3.8) , 24 (DLQI: 8.2±1.4, Skindex-16: 16.2; p-VAS: 2.6) and 36 (DLQI: 3.1±2.4; Skindex-16: 9.3±2.8; p-VAS: 2.8). Our study also confirmed the safety of tildrakizumab in real life settings, with no treatment discontinuation for inefficacy or adverse events reported during the study.Conclusions: our results confirm tildrakizumab as an effective option for the improvement of psoriasis patients' HRQoL.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A not-so healthy glow: a qualitative analysis of sunbed content and viewer engagement on social media. 不那么健康的光彩：对社交媒体上日光浴床内容和观众参与度的定性分析。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-14 DOI: 10.1093/ced/llae404

Claire Quigley, Claudine Howard-James, Helena Yhoo, Fei Lai, JiFung Yong, Michael Maguire, James Ralph, Anne-Marie Tobin, Gregg Murray

引用次数: 0

Paradoxical Psoriasiform Skin Eruption in Pediatric Patients with Inflammatory Bowel Disease Treated with TNFα Inhibitors. 接受 TNFα 抑制剂治疗的炎症性肠病小儿患者中出现的矛盾性牛皮癣样皮肤破溃。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-14 DOI: 10.1093/ced/llae432

Daniel Hilewitz, Sharon Yacobovitz, Shiran Reiss-Huss, Manar Matar, Yael Weintraub, Dror S Shouval, Lev Pavlovsky, Rivka Friedland

{"title":"Paradoxical Psoriasiform Skin Eruption in Pediatric Patients with Inflammatory Bowel Disease Treated with TNFα Inhibitors.","authors":"Daniel Hilewitz, Sharon Yacobovitz, Shiran Reiss-Huss, Manar Matar, Yael Weintraub, Dror S Shouval, Lev Pavlovsky, Rivka Friedland","doi":"10.1093/ced/llae432","DOIUrl":"https://doi.org/10.1093/ced/llae432","url":null,"abstract":"Background: Tumor necrosis factor α inhibitors (TNFαI)-induced psoriasiform eruptions are a well-known phenomenon among adults. However, data are limited regarding this reaction in children.Objectives: To describe in pediatric patients with inflammatory bowel diseases (IBD), the clinical characteristics of TNFαI-induced psoriasiform eruptions and the outcomes of various therapeutic options.Methods: We reviewed the medical charts of pediatric patients (aged <18 years old) with IBD who developed TNFαI-induced psoriasiform eruptions during 2006-2022.Results: Among 454 patients with IBD treated with TNFαI, 58 (12.8%) were diagnosed with TNFαI-induced psoriasiform eruptions, of whom 51 were included in the study. The female to male ratio was 1:1.3. The median age at skin eruption was 14.1 [interquartile range, 12.11-16.05] years. The median elapsed time to eruption appearance was 15 [interquartile range, 7-24] months after initiation of the treatment. All the patients were treated with topical steroids and 17 (33%) needed systemic treatment (phototherapy, methotrexate or acitretin). Sixteen patients (31%) needed to stop TNFαI treatment due to an intractable eruption. Female patients, patients with inflammatory alopecia and patients who were treated with methotrexate or phototherapy were more prone to stop TNFαI.Conclusions: TNFαI-induced psoriasiform eruptions are common in pediatric patients with IBD. The eruption may appear months or even years after treatment initiation. Almost one-third of the described patients had to replace their treatment due to a recalcitrant cutaneous eruption. This indicates that a multidisciplinary approach is required for effective management.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Program. 特应性皮炎与外周血管疾病之间的关系："我们所有人 "研究项目的一项横断面研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-10-14 DOI: 10.1093/ced/llae397

Sarah L Spaulding, Gloria F Chen, Andrew Craver, Jeffrey M Cohen

引用次数: 0